The use of antisense oligonucleotides in evaluating survivin as a therapeutic target for radiation sensitization in lung cancer

Biological Procedures Online

Volumn 6, Issue 1, 2004, Pages 250-256

  Shinohara, Eric T ^a   Hallahan, Dennis E ^a   Lu, Bo ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Antisense oligonucleotides; Luciferase; Survivin

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTISENSE OLIGONUCLEOTIDE; BETA ACTIN; COBALT 60; CYCLOOXYGENASE 2; DACTINOMYCIN; LUCIFERASE; PROTEIN P53; SURVIVIN;

ANALYTIC METHOD; ARTICLE; CANCER CELL; CELL CYCLE; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; PROTEIN EXPRESSION; PROTEIN TARGETING; RADIATION RESPONSE; RADIOSENSITIZATION; REPORTER GENE;

EID: 24744444762     PISSN: 14809222     EISSN: None     Source Type: Journal    
DOI: 10.1251/bpo95     Document Type: Article

References (19)

1. Lu B, Mu Y, Cao C, Zeng F, Schneider S, Tan J, Price J, Chen J, Freeman M, Hallahan DE. Survivin as a therapeutic target for radiation sensitization in lung cancer. Cancer Res 2004; 64(8):2840-2845.
2. Bao R, Connolly DC, Murphy M, Green J, Weinstein JK, Pisarcik DA, Hamilton TC. Activation of cancer-specific gene expression by the survivin promoter. J Natl Cancer Inst 2002; 94(7):522-528.
3. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003; 3(1):46-54.
4. Altieri DC, Marchisio PC, Marchisio C. Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab Invest 1999; 79(11):1327-1333.
5. Shih AH, Dai C, Hu X, Rosenblum MK, Koutcher JA, Holland EC. Dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis. Cancer Res 2004; 64(14):4783-4789.
6. Zhang Z, Li M, Wang H, Agrawal S, Zhang R. Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad Sci USA 2003; 100(20):11636-11641.
7. Weiss RH, Randour CJ. Attenuation of matrix protein secretion by antisense oligodeoxynucleotides to the cyclin kinase inhibitor p21(Waf1/Cip1). Atherosclerosis 2002; 161(1):105-112.
8. Hasholt L, Abell K, Norremolle A, Nellemann C, Fenger K, Sorensen SA. Antisense downregulation of mutant huntingtin in a cell model. J Gene Med 2003; 5(6):528-538.
9. Kamiyama M, Ichikawa Y, Ishikawa T, Chishima T, Hasegawa S, Hamaguchi Y, Nagashima Y, Miyagi Y, Mitsuhashi M, Hyndman D, Hoffman RM, Ohki S, Shimada H. VEGF receptor antisense therapy inhibits angiogenesis and peritoneal dissemination of human gastric cancer in nude mice. Cancer Gene Ther 2002; 9(2):197-201.
10. Lord RV, Salonga D, Danenberg KD, Peters JH, DeMeester TR, Park JM, Johansson J, Skinner KA, Chandrasoma P, DeMeester SR, Bremner CG, Tsai PI, Danenberg PV. Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg 2000; 4(2):135-142.
11. Gibson UE, Heid CA, Williams PM. A novel method for real time quantitative RT-PCR. Genome Res 1996; 6(10):995-1001.
12. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res 1996; 6(10):986-994.
13. Ormerod MG. Investigating the relationship between the cell cycle and apoptosis using flow cytometry. J Immunol Methods 2002; 265(1-2):73-80.
14. Otaki M, Hatano M, Kobayashi K, Ogasawara T, Kuriyama T, Tokuhisa T. Cell cycle-dependent regulation of TIAP/msurvivin expression. Biochim Biophys Acta 2000; 1493(1-2): 188-194.
15. Zhou M, Gu L, Li F, Zhu Y, Woods WG, Findley HW. DNA damage induces a novel p53-survivin signaling pathway regulating cell cycle and apoptosis in acute lymphoblastic leukemia cells. J Pharmacol Exp Ther 2002; 303(1):124-131.
16. Gewirtz AM, Stein CA, Glazer PM. Facilitating oligonucleotide delivery: helping antisense deliver on its promise. Proc Natl Acad Sci USA 1996; 93(8):3161-3163.
17. Yuen AR, Halsey J, Fisher GA, Holmlund JT, Geary RS, Kwoh TJ, Dorr A, Sikic BI. Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer. Clin Cancer Res 1999; 5(11):3357-3363.
18. Orr RM. Technology evaluation: fomivirsen, Isis Pharmaceuticals Inc/CIBA vision. Curr Opin Mol Ther 2001; 3(3):288-294.
19. Pisarev V, Yu B, Salup R, Sherman S, Altieri DC, Gabrilovich DI. Full-length dominant-negative survivin for cancer immunotherapy. Clin Cancer Res 2003; 9(17):6523-6533.